Bringing scientists together... Creating the future.

Developments in Protein Interaction Analysis
12–15 June 2016
Crowne Plaza Berlin City Center
Berlin, Germany

Join fellow scientific leaders at DiPIA 2016 conference and find out about the latest applications, results, and troubleshooting tips in biomolecular interaction analysis.

Leading experts from academia and industry share their success and failures in areas from basic research to quality control using Biacore systems.

DiPIA attracts  more than 200 delegates and speakers from around the world.

Conference topics include:

  • Biophysical characterization of biotherapeutics - Learn more
  • Low molecular weight drug discovery and characterization - Learn more
  • From basic research to advanced applications - Learn more
  • Comparability and quality control of biologics - Learn more

Connect and create the future – join DiPIA 2016 in Germany


Biophysical characterization of biotherapeutics

The field of biotherapeutics is at an exciting point in its development, with new generations of therapeutic antibodies, bioconjugates and vaccines coming to market. Advances in protein science and a greater emphasis on the importance of structure-function SAR, combined with clinical evidence are being used to accelerate the development of safe, highly effective therapies for unmet medical needs. We have seen innovation in the biotherapeutic space with the advent of bi-specifics, fusion protein therapeutics, antibody drug conjugates (ADC), and innovative vaccine therapies.

This session will highlight how Biacore systems using SPR technology have been employed in their discovery, development, and analysis. 

Low molecular weight drug discovery and characterization

A key focus for both the pharmaceutical industry and academic biomedical research is on the discovery and exploitation of new and/or novel drug targets – representing a substantial technological challenge in terms of both discovery platform and detection methods employed. SPR-based biosensors are now widely adopted in drug discovery due to the sensitivity required to detect and characterize the binding of low-affinity and low-molecular weight compounds to targets. This offers not only novel ways of hit finding but also efficiently identifies and advances true hits for chemistry and later stage biology by providing quantitative binding information for ranking compounds by their affinity and ligand efficiency. This information together with kinetic and thermodynamic information is critical to support ongoing structure–activity efforts during hit-to-lead development.

This session will provide insight into the current usage of Biacore systems in fragment based drug discovery (FBDD) and G protein coupled receptors (GPCR), one of the most medically important but difficult to work with class of targets.

From basic research to advanced applications

SPR-based biosensors has been a powerful, enabling technology in basic research since its inception in the early 1990s. It has been a symbiotic relationship, as research scientists have found novel ways to use Biacore systems, helping to advance the field as a whole. At the same time, improvements in instrument sensitivity, capability, and throughput have continued to help researchers achieve results that were not possible before.

This session will highlight scientists presenting their latest successes from the lab.

Comparability and quality control of biologics

Establishing Biosimilarity for complex biological products with several critical quality attributes is a challenging task. Accurate, precise and information-rich assays based on SPR have shown to be of great utility in supporting applications in regulated late-stage development, such as comparability assessment and manufacturing quality control.

This session will give an overview of current SPR trends in this field and examples of applications within in-process control, manufacturing, and QC. Biacore GxP applications and regulatory aspects will also be addressed. 

 



Sunday, 12 June 2016

10:00 – 18:00 Registration Open
10:00 – 16:00 Poster Drop-off
12:00 – 12:45 Lunch
12:45 – 13:45 Tutorial: Assay design and development
13:45 – 14:45 Tutorial: Evaluation of kinetic and affinity data
14:45 – 15:00 Coffee Break
15:00 – 16:00 Tutorials – parallel sessions
  • Best practices for fragment and small molecule analysis
  • Concentration and comparability assays
16:00 – 16:30 Coffee break
16:30 – 18:00 Workshop series – parallel sessions
16:30 – 18:00 Challenging targets

Challenging targets on Biacore™ systems: tips, tricks & best practices

Anna Moberg, GE Healthcare Life Sciences, Uppsala, Sweden

Investigation of membrane protein – ligand interactions by SPR
Sylwia Huber, Roche Innovation Center Basel, Basel, Switzerland

What lies beneath your binding curves: a key understanding required to design binding kinetics assays
Vishal Kamat, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
16:30 – 18:00

Best practices in biotherapeutic screening and characterization

Know your options: approaches to antibody screening
Brian Lang, GE Healthcare Life Sciences, Marlborough, MA, USA

Understanding bivalent interactions
Daniel Malashock, MSD, Palo Alto, CA, USA

Use of Biacore technology to determine affinity values for therapeutic Fab fragments which target multimeric proteins
Ana Carrion, Novartis, Cambridge, USA

19:00 Welcome Reception


Monday 13 June 2016

7:00 Registration Open
7:00 – 7:50 Breakfast
8:00 – 8:15 Foreword Lecture: Cindy Collins, GE Healthcare Life Sciences, CEO/GM, Purification & Analysis and Cell Therapy Businesses
8:15 – 10:00
Biophysical characterization of biotherapeutics, Session I

Optimization of antibodies and the role of affinity determinations
Trevor Wilkinson, MedImmune, Cambridge, UK

Anti-factor IXa/factor X bispecific IgG antibody (ACE910/emicizumab) for hemophilia A
Keiko Esaki, Chugai Pharmaceutical Co., Ltd, Gotemba City, Japan

SPR – Your companion from bench to bedside
Markus Sack, RWTH Aachen, Aachen, Germany
10:00 – 10:30 Coffee break & Exhibition
10:30 – 12:30 Low molecular weight drug discovery and characterization, Session I

The role of SPR biosensors in drug discovery
Helena Danielson, Uppsala University, Uppsala, Sweden

Development and applications of biosensor assays for wild type GPCRs
Iva Hopkins-Navratilova, University of Dundee/Kinetic Discovery, ltd., Scotland, UK

SPR and ITC-based small-molecule screening to find inhibitors of protein-protein interaction
Satoru Nagatoishi, The University of Tokyo, Tokyo, Japan
12:30 – 13:30 Lunch
13:30 – 15:00 Workshop series – parallel sessions

Best practices in biotherapeutic screening and characterization


Know your options: Approaches to antibody screening
Brian Lang, GE Healthcare Life Sciences, Marlborough, MA, USA

Understanding bivalent interactions
Daniel Malashock, MSD, Palo Alto, CA, USA

Use of Biacore technology to determine affinity values for therapeutic Fab fragments which target multimeric proteins
Ana Carrion, Novartis, Cambridge, USA

Best practices in low molecular weight drug discovery


The hitchhiker’s guide to best practices in low molecular weight drug discovery via SPR
Cynthia Shuman, GE Healthcare Life Sciences, Marlborough, MA, USA

Identifying small molecular fragment hits against PPI targets by SPR
Marta Westwood, UCB Pharma Ltd, Slough, UK

Critical analysis of biosensor data sets; making sure your conclusions and values are believable
Joe Papalia, Gilead Sciences, Inc., Foster City, CA USA
15:00 – 16:00 Poster session & Exhibition
16:00 – 16:30 Coffee break & Exhibition
16:30 – 18:30 Comparability and quality control of biologics Session

Development and validation of a novel SPR-based assay principle for bispecific molecules
Christian Gassner, Roche Diagnostics GmbH., Penzberg, Germany

Characterization of biosimilars by SPR
Shashank Sunkara, Momenta Pharmaceuticals, Cambridge, USA

A new player to support pharmaceutical drug development: SPR assays poaching in the field of QC, CMC and bioanalytical tasks
Christian Maasch, NOXXON Pharma AG, Berlin, Germany
18:30 Dinner on your own


Tuesday 14 June 2016

7:00 Registration Open
7:00 – 8:00 Breakfast
8:10 – 8:15 Opening remarks
8:15 – 10:00

Low molecular weight drug discovery & characterization, Session II

Metabolic enzyme inhibitor mechanism-of-action using the Biacore S200 A-B-A co-injection

Dominico Vigil, Agios Pharmaceuticals, Cambridge, MA, USA

SPR in GPCR targeted drug discovery

Andrei Zhukov, Heptares Therapeutics, Welwyn Garden City, UK

An Integrative structural biology study of FGFR1
Geoff Holdgate, AstraZeneca, Cambridge, UK

10:00 – 10:40 Coffee Break
10:40 – 12:30

Biophysical characterization of biotherapeutics, Session II

25 years of Biacore-Assisted Reagent Development

Michael Schraeml, Roche Diagnostics GmbH, Penzberg, Germany

Stoichiometric Activity of a Recombinant GPCR Extracellular Domain Fusion Protein
Bryan Tieman, Abbott Laboratories, Abbott Park, IL, USA

Simultaneous Engineering of Affinity and Stability of Antibodies and TCRs
Oliver Jianbing Zhang, Xiangxue Pharma, Guangzhou, China

12:30 – 13:30 Lunch
13:30 – 14:30 Roundtable Panel Discussions – parallel sessions
  • Challenges and recommended approaches when working with impure samples
  • Allosteric binders / blocked target & competition studies
  • Strategies for kinetic screening - how best to combine throughput and high data confidence
14:30 – 15:30 Poster session II
15:30 – 16:00 Coffee break
16:00 – 17:30

Workshop series – parallel sessions
Fc receptors


From structure to biological relevance: measuring Fc receptors by SPR

Stuart Knowling, Sartorius Stedim BioOutsource Ltd, Basel, Switzerland

IgG Fcγ receptor and neonatal receptor (FcRn) analyses; assay setup and challenges in data evaluation
Åsa Frostell, GE Healthcare Life Sciences, Uppsala, Sweden

Fc-receptors: challenging interaction partners in analytics
Florian Cymer, F. Hoffmann-La Roche Ltd, Basel, Switzerland

Challenging targets

Challenging targets on Biacore™ systems: tips, tricks & best practices
Anna Moberg, GE Healthcare Life Sciences, Uppsala, Sweden

Investigation of membrane protein - ligand interactions by SPR
Sylwia Huber, Roche Innovation Center Basel, Basel, Switzerland

What lies beneath your binding curves: a key understanding required to design binding kinetics assays
Vishal Kamat, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

19:00 Gala dinner and poster awards


Wednesday 15 June 2016

7:00 Registration Open
7:00 – 8:00 Breakfast
8:15 – 8:20 Opening remarks
8:20 – 9:20 Poster award winner presentations
9:20 – 9:30 Intro to main session
9:30 – 10:00

From basic research to advanced applications, Session I

What can we learn from kinetic analyses of methyl-CpG-binding domain/DNA interactions?

Ite A. Laird-Offringa, University of Southern California, Los Angeles, CA, USA

10:00 – 10:30 Coffee
10:30 – 12:15 From basic research to advanced applications, Session II

SPR-based analysis of kinase: substrate interactions

Matthias Knape, University of Kassel, Kassel, Germany

Impact of SPR studies on the study of disease-relevant protein interactions

Michael Ploug, University of Copenhagen, Copenhagen, Denmark

Biosensing of nucleic acid interactions by SPR: what else?

Carmelo Di Primo, University of Bordeaux, Pessac, France
12:15 – 12:30 Closing remarks
12:30 – 13:30 Lunch


Speakers Workshops


Main sessions

Biophysical Characterization of Biotherapeutics


Dr. Trevor Wilkinson

Medimmune, UK
Preliminary presentation title: Optimization of antibodies and the role of affinity determinations

Esaki Keiko

Chugai Pharmaceutical Co., Ltd. Research Division, Japan
Preliminary presentation title: Factor VIII Mimetic Anti-Factor IXa/Factor X Bispecific IgG Antibody for Hemophilia A

Dr. Michael Schraeml
Roche Diagnostics GmbH, Penzberg, Germany
Preliminary presentation title: 25 years of Biacore-Assisted Reagent Development

Oliver Jianbing Zhang, Vice President
Xiangxue Pharma, Life Sciences, China
Preliminary presentation title: Simultaneous Engineering of Affinity and Stability of Antibodies and TCRs

Markus Sack
Institute for molecular biotechnology, Aachen University, Germany
Preliminary presentation title: Surface Plasmon resonance studies

Bryan Tieman, Senior Scientist
Abbott Laboratories, US
Preliminary presentation title: Stoichiometric Activity of a Recombinant GPCR Extracellular Domain Fusion Protein

Low molecular weight drug discovery and characterization


Professor Helena Danielson (Keynote speaker)
Uppsala University, Sweden
Preliminary presentation title: The role of SPR biosensors in drug discovery

Mr Geoff Holdgate
Structure & Biophysics, Discovery Sciences, AstraZeneca, UK
Preliminary presentation title: Integrative structural biology approaches to study the DFG flip in FGFR1

Dr. Iva Hopkins Navratilova
Independent Investigator, University of Dundee/ CSO Kinetic Discovery, ltd. UK
Preliminary presentation title: TBD

Dominico Vigil, Biophysics Scientist
Agios Pharmaceuticals, US
Preliminary presentation title: Metabolic enzyme inhibitor mechanism-of-action using the Biacore S200 A-B-A co-injection

Dr. Satoru Nagatoishi
Department of Bioengineering, School of Engineering, The University of Tokyo, Drug Discovery Initiative, DDI, The University of Tokyo, Japan
Preliminary presentation title: SPR and ITC-based small-molecule screening to find inhibitors of protein-protein interactions.

Dr. Andrei Zhukov          
Heptares Therapeutics, UK
Preliminary presentation title: SPR in GPCR targeted drug discovery

From Basic Research to Advanced Applications


Dr. Michael Ploug
Finsen Laboratory & BRIC, Denmark
Preliminary presentation title: Impact of SPR studies on the study of disease-relevant protein interactions

Matthias Knape
Department of Biochemistry, University of Kassel, Germany
Preliminary presentation title: SPR-based analysis of kinase:substrate interactions

Dr. Carmelo Di Primo
University of Bordeaux, INSERM U1212 - CNRS UMR 5320, France
Preliminary presentation title: Biosensing of nucleic acid interactions by SPR: what else?

Ite Laird-Offringa
Norris Comprehensive Cancer Center, University of Southern California, US
Preliminary presentation title: What Can We Learn from Kinetic Analyses of Methyl-CpG-Binding Domain/DNA Interactions?

Comparability and quality control of biologics


Christian Maasch, Director Biophysical Analysis
NOXXON Pharma AG, Berlin, Germany
Preliminary presentation title: A new player to support pharmaceutical drug development: SPR assays poaching in the field of QC, CMC and bioanalytical tasks

Shashank Sunkara
Research Associate, Analytical Development, Momenta Pharmaceuticals, Cambridge, Massachusetts, USA
Preliminary presentation title:Characterization of Biosimilars by SPR

Christian Gassner
Roche Innovation Center Penzberg, Germany
Preliminary presentation title: Development and validation of a novel SPR-based assay principle for bispecific molecules

 

Workshops and abstracts

Best practices in biotherapeutic screening and characterization


Daniel Malashock, Senior Scientist

MSD, US
Preliminary presentation title: Understanding Bivalent Interactions

Ana Carrion
Novartis
How to evaluate kinetics for trimeric proteins


Learn more

Best practices in low molecular weight drug discovery


Joe Papalia

Gilead, US
Preliminary presentation title: Critical analysis of biosensor data sets; making sure your conclusions and values are believable


Learn more

Challenging targets


Dr. Sylwia Huber
Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Switzerland
Preliminary presentation title: Investigation of membrane protein - ligand interactions by SPR

Vishal Kamat
Regeneron Pharmaceuticals, US
Preliminary presentation title: Understanding What Lies Underneath Your Binding Curves: Key for Successful Characterization of Biomolecular Interaction

Learn more

Fc receptors


Dr Stuart Knowling

Sartorius Stedim BioOutsource, UK
Preliminary presentation title: TBD


Dr Florian Cymer

F. Hoffmann-La Roche Ltd., Switzerland
Preliminary presentation title: TBD

Learn more



In addition to the strong scientific program a number of other activities will be offered:

Tutorials 

Join our pre-conference tutorials offered at no extra cost on Sunday, 12 June.

  • Assay design and development
  • Evaluation of kinetic and affinity data
  • Best practices for fragment and small molecule analysis (this will be run in parallel with the concentration tutorial)
  • Concentration and comparability assays for biotherapeutics (this will be run in parallel with the fragment/LMW tutorial)

Workshops

Each 90 min session will provide educational and practical information on a range of application and methodology-related topics connected to Biacore systems. 

  • Challenging targets
  • Best practices in biotherapeutic screening and characterization
  • Best practices in low molecular weight drug discovery
  • Fc receptors

Roundtables

A small panel of experts will moderate discussion sessions (~ 60 min long) on a range of interesting topics.

  • Topic 1: Challenges and recommended approaches when working with impure samples
  • Topic 2: Allosteric binders / Blocked Target & competition studies
  • Topic 3: Strategies for kinetic screening- how best to combine throughput & high data confidence

Poster sessions

These sessions will provide an opportunity to have in-depth discussions with experienced Biacore system users.



Call for abstracts

The meeting will provide an excellent opportunity to network with other experts from academia and industry in the field of bio-molecular interaction analysis. The Organizing Committee invites you to present your results and ideas. We are currently calling for abstracts for oral presentations and posters in the following areas.

  • Biophysical characterization of biotherapeutics
  • Drug discovery and characterization
  • From basic research to advanced applications
  • Comparability and quality control of biologics

Oral abstract submission (closed)

Abstracts should be no more than 500 words and must describe original work; they should contain the author’s name, affiliation, email address, topic, and description.

  • Please submit your abstract electronically in a PDF or Word document to DiPIA.2016@ge.com
  • The submission deadline was 7 January 2016 (closed)
  • Authors whose abstracts are accepted for presentation will be notified by 31 January, 2016

Poster abstract submission (closed)

Conference attendees are strongly encouraged to submit abstracts for posters to ensure they receive the broadest coverage. The authors of two to four abstracts (including both poster and oral abstract submissions) will have the opportunity to present their data during the meeting agenda. This selection will be decided by the organizer prior to the conference.

The author of the best scientific poster (to be selected by the meeting attendees) will receive an award at the gala dinner and also given the opportunity to present the data in a 15 min time slot during the poster award session.

We require that at least one person (responsible for the poster/poster representative) will stand next to his/her scientific poster during one of the two dedicated poster sessions to enable symposium participants to ask questions and discuss the work.

Poster abstracts should be no more than 500 words and must describe original work; they should contain the author’s name, affiliation, email address, topic, and description.

  • Posters should be A0 size (i.e., 84 × 119 cm) and portrait format
  • Please submit your abstract electronically in a PDF or Word document to DiPIA.2016@ge.com
  • The submission deadline is 20 May, 2016
  • The receipt and acceptance of posters will be confirmed by email

Information about selection criteria can be found here.


The meeting is organized by GE Healthcare. The registration fee covers all conference material, coffee breaks, lunch, the Welcome Reception and Gala Dinner. Accommodation is not included.

Register today

Individual fee early bird (offer ends March 2016) Individual fee (valid from March 2016-May 2016) One day pass (1 day conference only, not the welcome reception or gala dinner) Guest pass (welcome reception, gala dinner) Multi-registration deals early: 3 registrations with 10% discount (offer ends March '16) Multi-registration deals: 3 registrations with 10% discount (March '16 -  May '16)
€ 655 € 750 € 180 € 200 € 1768 € 2025

Individual fee early bird (offer ends March 2016) € 655
Individual fee (valid from March 2016-May 2016) € 750
One day pass (1 day conference only, not the welcome reception or gala dinner) € 180
Guest pass (welcome reception, gala dinner) € 200
Multi-registration deals early: 3 registrations with 10% discount (offer ends March '16) € 1768
Multi-registration deals: 3 registrations with 10% discount (March '16 -  May '16) € 2025

Venue

Crowne Plaza Berlin City Center
Address: Nürnberger Str. 65, 10787 Berlin, Germany
Phone:+49 30 210070

Accommodations can be booked at a cost of 149 Euro per night.
Hotel accommodation is not included in the conference fee.

 



2016 © GE Healthcare Privacy Policy | Terms & Conditions | Trademarks | GE Healthcare | GE Healthcare Life Sciences